Jeffrey Copeland
Psychiatric/Mental Health, Adult · Leavenworth, KSNPI 1811905078
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,218 of the $1,414 with a category attached, or 86.2%. It is spread thinly across 16 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations.
Across 71 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$336
- Alkermes, Inc.$168
- Otsuka America Pharmaceutical, Inc.$151
- Teva Pharmaceuticals USA, Inc.$121
- Lundbeck LLC$94
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$94
- plus $450 from 10 others
What the payments were for
- Food & beverage$1,21886%
- Education$19514%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $336 |
| Alkermes, Inc. | 9 | $168 |
| Otsuka America Pharmaceutical, Inc. | 7 | $151 |
| Teva Pharmaceuticals USA, Inc. | 2 | $121 |
| Lundbeck LLC | 5 | $94 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $94 |
| Supernus Pharmaceuticals, Inc. | 6 | $93 |
| Vanda Pharmaceuticals Inc. | 3 | $71 |
| Johnson & Johnson | 3 | $61 |
| Tris Pharma Inc | 3 | $59 |
| Corium, LLC | 3 | $55 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Almatica Pharma LLC | 2 | $27 |
| Indivior Inc. | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
How this compares
Too few psychiatric/mental health, adult providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 135 | $619,080 |
| RexultiBrexpiprazole | 184 | $216,081 |
| AustedoDeutetrabenazine | 30 | $186,565 |
| Invega TrinzaPaliperidone Palmitate | 13 | $147,461 |
| Abilify AsimtufiiAripiprazole | 22 | $127,902 |
| IngrezzaValbenazine Tosylate | 12 | $102,834 |
| VraylarCariprazine Hcl | 74 | $99,853 |
| Abilify MaintenaAripiprazole | 30 | $89,030 |
| LybalviOlanzapine/Samidorphan Malate | 35 | $56,218 |
| Invega SustennaPaliperidone Palmitate | 24 | $48,672 |
| Aripiprazole | 251 | $38,375 |
| SpravatoEsketamine Hcl | 30 | $37,535 |
| AristadaAripiprazole Lauroxil | 15 | $35,960 |
| PerserisRisperidone | 12 | $35,784 |
| CaplytaLumateperone Tosylate | 14 | $31,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $121 | $805,645165 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Asimtufii, Abilify Maintena | $151 | $433,012236 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Spravato | $61 | $233,66867 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $14 | $102,83412 claims |
| AbbVieVraylar | $336 | $99,85374 claims |
| Alkermes, Inc.Lybalvi, Aristada | $168 | $92,17750 claims |
| Indivior Inc.Perseris | $17 | $35,78412 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $94 | $31,62814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, adult providers in Kansason file to place this against a meaningful peer group, so we don't.
Other psychiatric/mental health, adult in Leavenworth
- Debra KirmerTopeka$856
- Terry AndersonWichita$653
- Finnian McCulloughLawrence$606
- Maria IlardiLawrence$499
- Kathryn NobleTopeka$113
- Noreen ThompsonKansas City$90
- Marsha Bacote-AlleyneAuburn$24
- Sabra TiepermanManhattan$17
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.